All CD137 reagents are produced in house and quality controlled, including 3 CD137 Antibody, 60 CD137 Gene, 11 CD137 Lysate, 11 CD137 Protein, 3 CD137 qPCR. All CD137 reagents are ready to use.
Recombinant CD137 proteins are expressed by HEK293 Cells with fusion tags as C-human IgG1-Fc & His, C-His & C-human IgG1-Fc, C-human IgG1-Fc, C-His, C-rabbit IgG-Fc.
CD137antibodies are validated with different applications, which are ELISA.
CD137cDNA clones are full length sequence confirmed and expression validated. There are 13 kinds of tags for each CD137 of different species, especially GFP tag, OFP tag, FLAG tag and so on. There are three kinds of vectors for choice, cloning vector, expression vector and lentivrial expression vector.
Expression host: HEK293 Cells
CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed mainly on activated CD4+ and CD8+ T cells, and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. Upon ligand binding, 4-1BB is associated with the tumor necrosis factor receptor–associated factors (TRAFs), the adaptor protein which mediates downstream signaling events including the activation of NF-kappaB and cytokine production. 4-1BB signaling either by binding to 4-1BBL or by antibody ligation delivers signals for T-cell activation and growth, as well as monocyte proliferation and B-cell survival, and plays an important role in the amplification of T cell-mediated immune responses. In addition, CD137 and CD137L are expressed in different human primary tumor tissues, suggesting that they may influence the progression of tumors. Crosslinking of CD137 on activated T cells has shown promise in enhancing anti-tumor immune responses in murine models, and agonistic anti-CD137 antibodies are currently being tested in phase I clinical trials.